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Original Article
NEMO Gene Mutations in Chinese Patients With
Incontinentia Pigmenti
Pa-Fan Hsiao,1,4* Shuan-Pei Lin,2,4,5 Shu-Shien Chiang,3 Yu-Hung Wu,1,4
Hsiu-Chin Chen,1,6 Yang-Chih Lin1,4,7
Background/Purpose: Incontinentia pigmenti is a rare, X-linked, dominant genodermatosis affecting
skin, teeth, eyes, and central nervous system. Symptoms are associated with mutations in the nuclear factor-
kappa B essential modulator (NEMO) gene on chromosome Xq28. Here, a subpopulation of Chinese patients
with incontinentia pigmenti were examined to investigate the frequency and pattern of NEMO mutations,
and to analyze their clinical features.
Methods: From January 1996 to August 2006, 52 participants (21 probands and 31 family members) were
screened for symptoms of incontinentia pigmenti and NEMO gene mutations. We designed a NEMO-specific
PCR primer, referred to as In2S, to detect a deletion of exon 4–10 of the NEMO gene, which represents the
mutation most frequently associated with incontinentia pigmenti. For participants without this deletion,
all exons were sequenced to screen for other NEMO mutations. In addition, the clinical manifestations
and family histories of the participants were analyzed.
Results: Exon 4–10 was deleted in 13 probands, and one proband had a novel point mutation (G549C)
in exon 5 that converted a glutamine to a histidine. Seven probands (33%) had no mutation in any of the
exons of the NEMO gene. One of four participants who presented with hyperpigmentation also had the
exon 4–10 deletion. One patient had a positive family history before the study took place, but no NEMO
mutation was identified in any of the family members. Remarkably, the mothers of three of the probands
exhibited the exon 4–10 deletion; however, their clinical manifestations were subtle and unrecognizable.
Conclusion: Mutational analysis of the NEMO gene was helpful in diagnosing incontinentia pigmenti
among participants with a nearly normal phenotype or an incomplete form of the disease that only caused
hyperpigmentation symptoms.
Key Words: incontinentia pigmenti, NEMO gene
Incontinentia pigmenti is a rare, X-linked, domi-
nant genodermatosis that is mostly diagnosed in
females. The disease is usually lethal in males.
Primarily of ectodermal origin, incontinentia
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pigmenti is a multisystemic disorder characterized
by abnormalities of the skin, hair, teeth, eyes, and
central nervous system.1
Diagnosis of incontinentia pigmenti depends
on clinical criteria and patient family history.2 Early
diagnosis is typically based on the observation of
skin lesions in affected newborns. Cutaneous
manifestations tend to be patterned along the
lines of Blaschko and often progress from blis-
ters (stage I) to verrucous lesions (stage II), linear
and pigmented patches (stage III), and finally
hypopigmented and atrophic lesions (stage IV).
These stages can appear in sequence, or they may
overlap. Despite these manifestations, patients’
presentations are extremely variable, and the di-
agnosis can easily be missed in patients whose
skin lesions are subtle or in patients who present
with only hyperpigmented streaks or whorls.1
Missed diagnoses limits accurate genetic coun-
seling for affected families.
The recent identification of nuclear factor-
kappa B (NF-κB) essential modulator (NEMO) as
the causative gene has greatly helped in resolving
the difficulty in diagnosis.1,3 Along with IKKα and
IKKβ, the NEMO protein, also known as IKKγ, is a
subunit of IκB kinase. IκB kinase is an essential
link in the activation of NF-κB, and loss of NEMO
function abolishes NF-κB activation. NF-κB is re-
sponsible for preventing apoptosis, particularly in
response to tumor necrosis factor-α.4,5 Deletion of
exon 4–10 of the NEMO gene causes 80–90% of
all cases of incontinentia pigmenti.3,6,7
The aim of this study was to examine the 
frequency and pattern of NEMO mutations in
Chinese patients with incontinentia pigmenti and
to analyze the clinical manifestations of these
patients and their family histories.
Materials and Methods
Participants
Between 1996 and 2006, we identified 21 pa-
tients with incontinentia pigmenti from the files of
the Departments of Dermatology and Pediatrics.
The diagnoses were made according to the criteria
defined by Landy and Donnai.2 This study was
conducted according to the guidelines of, and was
approved by, our hospital’s institutional review
board. Blood samples were obtained from all
probands (n = 21) and available family members
(n = 31; total = 52) after they provided written 
informed consent.
Detection of NEMO mutations
DNA samples were extracted from peripheral
whole-blood samples. We used a genomic blood
DNA purification kit (GFX; GE Healthcare Bio-
Sciences, Piscataway, NJ, USA), according to the
manufacturer’s instructions. Primers used to am-
plify deletions of exon 4–10 of the NEMO gene
were In2S and JF3R (Table 1, Figure 1A). Internal
controls were JF3R and Rep3s (Table 1, Figure
1A).2,8,9 Primer In2S is a newly designed primer
located in intron 2. This primer is fully comple-
mentary to the NEMO gene, but not to the NEMO
pseudogene (Figure 1B).10 The JF3R primer is com-
plementary to both the NEMO gene and NEMO
pseudogene. The NEMO pseudogene, which is
oriented in the opposite direction to NEMO, spans
from 282 bp upstream of exon 3.0–9.9 kb down-
stream of exon 10 and is 30 kb distant from the
NEMO gene on Xq28. Because of the substantial
sequence similarity between the NEMO pseudo-
gene and the NEMO gene, nonspecific primers,
including 3FH and JF3R, do not allow discrimina-
tion between rearrangements of the two genes.3,8
To detect NEMO mutations, primer pairs were
used to amplify all coding regions, intron-exon
boundaries, and promoters (Table 1).
Polymerase chain reaction (PCR) were per-
formed in a total volume of 20 μL that contained
300 ng of genomic DNA, 0.5 μmol/L of each
primer, 0.25 μmol/L deoxyribonucleotide triphos-
phates, 1.5 μmol/L of MgCl2, and 1 U of Super-
thermo Gold Taq polymerase in a DNA thermal
cycler (Perkin-Elmer, Applied Biosystems, Foster
City, CA). PCR was started with 5 minutes at
94°C, followed by a total of 35 cycles of 30 sec-
onds of denaturing at 94°C, 30 seconds of an-
nealing at optimized temperature (Table 1), and
60 seconds of elongation at 72°C. After PCR, the
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Table 1. Nuclear factor-kappa B essential modulator gene sequencing primer pairs
Gene Primer Sequence Product (bp) Tm (°C) Reference
Rep3s* 5-CTC TTT TGA CAA GAA CAC CGG-3 733 68 9
JF3R* 5-CTC GGA GAC ACA GGA ACC AGCA-3 733 68 3
NEMO-exon1a forward 5-GGA AGT CAG CCC AGA AAT GT-3 302 52 3
reverse 5-GTA CTT ACT GCC CCC TTC CA-3
NEMO-exon1b forward 5-GGG CGG GGC TTG TGT TTT TA-3 297 55 3
reverse 5-AGA AGC GCG GAG CAG GAA CG-3
NEMO-exon1c forward 5-TTC CTG CTC CGC GCT TCT GG-3 334 52 3
reverse 5-CCA GGA GAG CCC ATT CAT TC-3
NEMO-exon2 forward 5-GCA TCC TGA TAC ACT AGG TGA-3 452 53
reverse 5-TCT ACT TCC TGA AAC CAA GAG-3
In2s* 5-CAG TGC CTG GCC AAC ACG TAC-3 698 60
NEMO-exon3 reverse 5-TCG CTC ACC GTA ACC TGT GTC-3 698 60
NEMO-exon4 forward 5-GGT TAA GGT GGG CAG CTG GG-3 797 53
reverse 5-GCA TCC CTG GGC AGG AAC AT-3
NEMO-exon5–6† forward 5-GGC GAC CCC ATC CTT TTC TT-3 1833 62
reverse 5-TGC AGC CTG ACA CAG GTCT-3
NEMO-exon7–9 forward 5-CTG GGC TGA CGA GGC TCC GT-3 1460 63
reverse 5-TGT AAG ACC AGG AGC CGC CG-3
NEMO-exon10 forward 5-AGG GAG GCA TGC CGT GGT AGC-3 1026 61
reverse 5-CGG GCT TTC CCA CCT CCT CCTT-3
IP-exon5‡ forward 5-CAT CAG CTC GCA GTC ACA GG-3 357 57 3
reverse 5-CCG ACA CTT CTC AGC CTT TC-3
IP-exon6‡ forward 5-AAG GGG GTA GAG TTG GAA GC-3 277 53 3
reverse 5-AGG CAA GTC TAA GGC AGG AC-3
*Used in test for deletion exon 4–10 with SuperthermoGOLD Taq at Tm 68°C; †known to be specific for the NEMO gene but not the
deltaNEMO pseudogene; ‡known to be specific for both the NEMO gene and the deltaNEMO pseudogene. NEMO = nuclear factor-
kappa B essential modulator; Tm = melting temperature.
reaction products were separated by 2% agarose
gel electrophoresis.
Clinical features
Two dermatologists (Dr P.F. Hsiao and Dr Y.H.
Wu) and one pediatrician (Dr S.P. Lin) reviewed
all available data concerning the probands and
their female relatives and performed physical 
examinations when possible.
Results
NEMO mutations
The exon 4–10 deletion of the NEMO gene was
detected in 13 (61.9%) of the 21 clinically de-
fined probands (Table 2). PCR results showed a
2243-bp product and a 733-bp internal control
band (Figure 1). The remaining eight partici-
pants did not have this common deletion, and
the respective PCR results showed only the 733-
bp internal control, confirming the quality of
PCR. One participant had a point mutation
G549C in exon 5 that converted a glutamine to
histidine (Figure 3). This missense mutation was
found in only the proband and not in her
healthy parents. The only male patient had a
normal karyotype, and no NEMO mutation was
detected. The clinical presentations of patient 15
in Figure 2 (Figure 4A) and the only male patient
(Figure 4B) were typical linear vesicles (stage I)
on first diagnosis.
The exon 4–10 deletion was also detected in
three mothers of participants with incontinentia
pigmenti. Another mother of a proband had a
history of vesicles in infancy which was diagnosed
as incontinentia pigmenti, but the common dele-
tion was not detected. These four mothers were
diagnosed with incontinentia pigmenti (female
relatives of probands) based on their molecular
findings and clinical history.
Clinical features
Table 2 summarizes the 21 probands who par-
ticipated in this study, including clinical presen-
tations, physical findings, imaging results, and
follow-up data. The frequency of neurological
and eye abnormalities were 23.8% (5/21) and
28.6% (6/21), respectively (Table 2).
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A
1–2
Cen Tel
Tel
In2S Rep3s Rep3s
NEMO pseudo NEMO
Rep3s Rep3sJF3R
JF3R JF3R
JF3R
4–10 10–4 33E E
733 bp 733 bp
733 bp 733 bp
2243 bp
E E
1–2
Cen
In2S Rep3s Rep3s In2S
3E E E E3
(1)
NEMO(153945059)
DeltaNEMO(142421568)
Consensus (13601)
Consensus (27601)
Consensus (13701)
DeltaNEMO(142407574)
DeltaNEMO(142421468)
Consensus (13701)
NEMO(153945148)
DeltaNEMO(142421468)
NEMO (153957815)
NEMO (153957915)
GTCTTCGGGCAGGGGTTTGAGTGCAGTGTGCCTGCCGAGAGGTTCTGCAGTTCCGAGCACCATCATTTTCTCCTCCTCAGACCCCTTGGTTCTCCTTCCA
GTCTTCGGGCAGGGGTTTGAGTGCAGTGTGCCTGCCGAGAGGTTCTGCAGTTCCGAGCACCATCATTTTCTCCTCCTCAGACCCCTTGGTTCTCCTTCCA
GTCTTCGGGCAGGGGTTTGAGTGCAGTGTGCCTGCCGAGAGGTTCTGCAGTTCCAGCACCATCATTTTCTCCTCCTCAGACCCCTTGGTTCTCCTTCCA
CGTCCTGGCAGCTGCTTCGCAGGCTCCTTGCTGGTTCCTGTGTCTCCGAGCTGACTCCCGAATTCTCTTCCTCTCCTTGCTCAGACACTGCCCCTTTGTG
CGTCCTGGCAGCTGCTTCGCAGGCTCCTTGCTGGTTCCTGTGTCTCCGAGCTGACTCCCGAATTCTCTTCCTCTCCTTGCTCAGACACTGCCCCTTTGTG
CGTCCTGGCAGCTGCTTCGCAGGCTCCTTGCTGGTTCCTGTGTCTCCGAGCTGACTCCCGAATTCTCTTCCTCTCCTTGCTCAGACACTGCCCCTTTGTG
CGTACTTTAAGTGAAGCTGATGTGTTTGGTGTTATTTTGTTGCAGAAAGTGAGGGGCATTAGTGTAAAGGATTTTGAAG
-------------------CGTACTTTTAAGTGAAGCTGATGTGTTTGGTGTTATTTTCTTGCAGAAAGTGAGGGGCATTAGTGTAAAGGATTTTGGAAG
TTTAAAGTGACATTTGAGACGTACTTTTAAGTGAAGCTGATGTGTTTGGTGTTATTTTCTTGCAGAAAGTGAGGGGCATTAGTGTAAAGGATTTTGGAAG
GTCTGGAGCTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCACAGTGCCTGGCC---------AACA---
GTCTGGAGCTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCACAGTGCCTGGCC--------AACA--
GTCTCAATCTCCTGACCTCA--TGATCCGCCCACCTCGGCCTCCCAAAGTGTTGGGATTACAGGCGTGAGCCACCCCACCCAGCCAAAAATAAAAAATTT
(2)
<JF3R (153957885-153957865)
Figure 1. (A) Primer positions for multiplex polymerase chain reaction to detect nuclear factor-kappa B essential modu-
lator (NEMO) gene rearrangements. In2S is specific for the NEMO gene. JF3R is complimentary to both the NEMO gene
and NEMO pseudogene. (B) Sequence dissimilarity between the NEMO gene (position 153945132 to 153945152) and
the deltaNEMO pseudogene. Consensus base pairs are indicated.
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C T G C A G/C 
Arg Gln/His Leu 
182 183 184 
C G G 
Figure 3. Sequence analysis of exon 5 of the nuclear factor-
kappa B essential modulator gene in a proband who was
heterozygous for G549C, a de novo missense mutation.
This resulted in a change of codon 183 CAG (glutamine,
Gln) to CAC (histidine, His). Arg = arginine; Leu = leucine.
Frequencies of cutaneous manifestations were
95.2% (20/21) for hyperpigmented streaks, 81.0%
(17/21) for vesicular eruptions, and 38.1% (8/21)
for warty lesions. Three probands (14.3%) exhib-
ited dental abnormalities. One proband  (4.8%)
had one hairless patch on the right side of the
scalp in the parietal area, which was noted after
birth. Two probands had congenital heart disease
(9.5%). One proband (4.8%) had developmental
bony defects of both feet. In the latter proband, ra-
diographs revealed an absence of distal phalanges
15
N
B
8 
m
o
I, 
II,
 II
I
–
–
–
D
EL
Fa
m
ili
al
M
 1
5
35
 y
r
35
 y
r
–
–
–
–
D
EL
16
*
N
B
8 
m
o
I, 
III
–
–
–
–
Sp
or
ad
ic
17
N
B
25
 y
r
I, 
III
H
em
ip
ar
es
is
, a
bn
or
m
al
 C
T
N
ys
ta
gm
us
, l
os
s 
of
 v
is
io
n
–
D
EL
Fa
m
ili
al
M
 1
7
53
 y
r
53
 y
r
–
–
–
–
D
EL
18
N
B
4 
m
o
I, 
II,
 II
I
–
–
–
D
EL
Sp
or
ad
ic
19
N
B
4 
m
o
I, 
III
N
or
m
al
 b
ra
in
 s
on
og
ra
m
 &
 
–
–
–
Sp
or
ad
ic
M
RI
20
N
B
4 
m
o
I, 
II,
 II
I
N
or
m
al
 b
ra
in
 s
on
og
ra
m
 
–
–
D
EL
Sp
or
ad
ic
21
16
 y
r
16
 y
r
III
–
–
–
D
EL
Sp
or
ad
ic
*P
at
ie
nt
 1
6 
w
as
 t
he
 o
nl
y 
m
al
e 
pa
tie
nt
; 
† I
 =
cu
ta
ne
ou
s 
bl
is
te
rin
g;
 I
I 
=
ve
rr
uc
ou
s 
le
si
on
s;
 I
II 
=
lin
ea
r 
an
d 
pi
gm
en
te
d 
pa
tc
he
s;
 I
V 
=
hy
po
pi
gm
en
te
d 
an
d 
at
ro
ph
ic
 le
si
on
s.
 M
 =
m
ot
he
r 
of
; 
N
B 
=
ne
w
 b
or
n;
 
N
EM
O
 =
nu
cl
ea
r 
fa
ct
or
-k
ap
pa
 B
 e
ss
en
tia
l m
od
ul
at
or
; C
T 
=
co
m
pu
te
d 
to
m
og
ra
ph
y;
 M
RI
 =
m
ag
ne
tic
 r
es
on
an
ce
 im
ag
e;
 D
EL
 =
de
le
tio
n 
of
 e
xo
n 
4–
10
 o
f 
N
EM
O
; G
54
9C
 =
a 
no
ve
l p
oi
nt
 m
ut
at
io
n 
(G
54
9C
) i
n
N
EM
O
 e
xo
n 
5.
Figure 2. Deletions of exons 4–10 of the nuclear factor-
kappa B essential modulator gene. A 2243-bp band was
found in the proband of patient 15 (P) and her mother
(M). In all specimens, an internal control of 733-bp band
was found. B = the older brother of the patient; F = the 
father of the patient; MW = the molecular weight marker
bands.
MW P F M B 
2243-bp
733-bp
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in both big toes and an absence of the middle
and distal phalanges of the 2nd, 3rd, 4th and 5th
toes on her left foot.
One of the mothers recalled having vesicles
during infancy, and two had hyperpigmented
streaks. None of the four mothers with inconti-
nentia pigmenti had neurological or ophthalmo-
logic manifestations.
Discussion
NEMO mutations were detected in 14 (66.7%) of
21 participants with incontinentia pigmenti, 13
of which were the common exon 4-10 deletion,
whereas the other was a novel mutation. Our re-
sults are similar to a recent review that reported
that 60–80% of incontinentia pigmenti cases stud-
ied had NEMO mutations.11 Among our cases,
four were familial and 17 were sporadic; of those
that had NEMO mutations, three were familial
and 11 were sporadic. This also agrees with the
pattern seen in the literature.11 Most of the reports
on incontinentia pigmenti are from Western pop-
ulations. Few reports on incontinentia pigmenti
from East Asian populations have been published.
Some studies have reported on Chinese from
China and Taiwan,12−17 another on 40 cases from
Korea,18 and two reports from Japan.19,20 In gen-
eral, the frequency of NEMO mutations in incon-
tinentia pigmenti is similar to that in Western
populations. Because many cases of incontinen-
tia pigmenti are in patients without family his-
tory of incontinentia pigmenti, and thus de novo
mutations, we expect that Asian populations are
equally susceptible to this rare genetic disease.
One proband had a novel missense mutation
in exon 5 of the NEMO gene. This alteration
changed a glutamine to histidine (Q183H) in the
coiled-coil 1 (CC1) domain of the NEMO protein
(for a mutation and domain map of NEMO, see6).
Defects in the CC1 domain may affect assembly
of the IKK complex, which is essential for its ki-
nase activity.7 Several reports describe a 10–16%
rate of small mutations of the NEMO gene, in-
cluding deletions, substitutions, and insertions.3,6,7
These mutations are evenly scattered along the
gene, consistent with the finding that the entire
NEMO protein sequence is important to its func-
tion.6,7,21,22 These mutations commonly cause
frame shifts and premature truncation of the
NEMO protein.6,17,23
Most single-nucleotide substitutions are CT
transitions.7,23 Our finding of a GC transition
is rarely reported. Among previously described
small nucleotide substitutions, only six were mis-
sense mutations.3,6,7 Except for one missense mu-
tation (M407V) that occurred in exon 10,3 all
others occurred in the CC1 domain.6,7 These 
N-terminal, disease-linked mutations affect activ-
ity less than C-terminal disease-linked mutations,
which produce a truncated protein.7 A deletion
A B
Figure 4. Cutaneous manifestations of incontinentia pigmenti. (A) Linear vesicles (Stage I) were scattered on the trunk
and limbs of patient 15 (female). (B) Linear vesicles (Stage I) were seen along the left leg of patient 16 (male).
Chinese incontinentia pigmenti NEMO gene mutations
J Formos Med Assoc | 2010 • Vol 109 • No 3 199
of 37 nucleotides, Q183fsX56, was reported in
the same location as the location studied herein,
and resulted in symptoms associated with incon-
tinentia pigmenti.
The mother of only one of the probands re-
called having vesicular eruption in infancy; no
pigmented lesion appeared later in life. However,
with genetic diagnostic testing, we identified three
other mothers with the NEMO exon 4–10 dele-
tion. When we reexamined these mothers, only
one had linear pigmentation on her limbs. The
other two denied having any cutaneous manifes-
tations. None of these adults had stage IV hy-
popigmented reticulate lines, which have been
reported to appear in older patients with inconti-
nentia pigmenti.24 No dental, hair, ocular, or
nervous complications were found.
Most of our cases of familial incontinentia
pigmenti were diagnosed using molecular tests.
The mothers’ symptoms were relatively mild and
unidentified. Three of the four affected mothers
were diagnosed with NEMO mutations. The
identification of familial or sporadic cases is im-
portant in genetic counseling. Our results are in-
consistant with a previous report in which
secondary cases (female relatives of probands)
were identified on the basis of clinical criteria
alone.24 It is likely that incontinentia pigmenti in
mildly affected patients (even those without skin
lesions) is often undiagnosed and underrepre-
sented because older patients have poor recall,
and their mothers may no longer be alive.24
Genetic testing is especially helpful in diagnos-
ing incontinentia pigmenti in such patients.
All but one of the probands studied had linear
hyperpigmented streaks or whorls; in four of the
participants (3 probands and 1 secondary case of
incontinentia pigmenti), these were the only cu-
taneous manifestations observed. Differential di-
agnosis of reticulate hyperpigmentation should
be considered in patients with such findings.25
Typically lethal, incontinentia pigmenti is only
seen in males in exceptional circumstances. Rea-
sons that might account for incontinentia pig-
menti in our male patient include balancing of the
mutation due to Klinefelter syndrome (47, XXY),
somatic mosaicism, carrying a less lethal hypo-
morphic allele, or large-scale chromosome re-
arrangements affecting NEMO that might be
missed by molecular analysis.3,11 Although the di-
agnosis was confirmed as incontinentia pigmenti
based on the participant having typical linear vesi-
cles as a newborn (Figure 4B) and streaks of hy-
perpigmentation at 2 months of age and vesicle
histology typical of incontinentia pigmenti, the
male patient’s karyotype did not reveal any abnor-
malities, ruling out chromosomal rearrangements
or Klinefelter syndrome. The linear vesicles were
not seen on all regions of the body, suggesting mo-
saicism. We only analyzed blood samples, there-
fore we could have missed a NEMO mutation due
to a somatic mosaicism causing the blood cells to
have a normal genotype. Unless there was such
mosaicism, there was no NEMO mutation, hypo-
morphic or otherwise. Though most cases of in-
continentia pigmenti have now been identified as
NEMO mutations, many still have an unknown
etiology and the patient may fall into this group.
Incontinentia pigmenti may be difficult to 
diagnose in some cases due to low penetrance,
mosaicism or X inactivation skewing. This report
shows that both familial and sporadic cases of
incontinentia pigmenti occur in the Chinese
population, and that the most common molecu-
lar cause, the exon 4–10 deletion, is the same as in
other populations. Recently, a male patient with
a NEMO mutation presenting with ectodermal
dysplasia with immunodeficiency was treated
with stem cell transplant.26 Molecular screening
of NEMO should be performed in any clinically
suspected case. Being aware of the molecular de-
fects may be useful to exclude other differential
diagnoses, to design treatment strategies, and to
offer genetic counseling.
In conclusion, we examined Chinese patients
with incontinentia pigmenti. Thirteen (61.9%)
probands had the common deletion of exon
4–10, while one proband (4.7%) had a novel
point mutation (G549C) in exon 5 that resulted
in a conversion from glutamine to histidine. We
demonstrate that genetic testing which specifi-
cally detects the common deletion in the NEMO
P.F. Hsiao, et al
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gene is useful in diagnosing a subset of inconti-
nentia pigmenti that results in a normal or mild
phenotype.
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